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This editorial refers to ‘Early dyspnoea relief in acute
heart failure: prevalence, association with mortality, and
effect of rolofylline in the PROTECT Study’†, by
M. Metra et al., on page 1519
Acute heart failure syndromes (AHFS) has been defined as new
onset or recurrence of gradually or rapidly worsening signs and
symptoms of heart failure (HF) necessitating urgent or emergency
therapeutic intervention.1 The number of hospitalizations for
AHFS continues to increase and they account for 1 million
admissions annually in both Europe2 and the USA.3 Dyspnoea is
the most common presenting symptom among patients hospital-
ized for AHFS,4,5 making it a clinically relevant therapeutic target
and endpoint for clinical trials and regulatory approval.6–8.
Although dyspnoea and other signs and symptoms of HF appear
to improve in response to standard therapy alone during initial
stabilization4 and hospitalization,9–11 many patients are being
sent home with persistent signs and symptoms of HF.12 In addition,
the post-discharge mortality and HF rehospitalization rate remain
as high as 15 and 30%, respectively, within 60–90 days.13 Thus,
there is a critical unmet need in AHFS to develop novel agents
capable of safely improving signs and symptoms of HF beyond stan-
dard therapy during hospitalization and reducing the early post-
discharge event rate.14
Metra et al.15 address whether dyspnoea relief predicts short-
term morbidity and mortality in a post-hoc analysis of the Placebo-
controlled Randomized Study of the Selective A1 Adenosine
Receptor Antagonist Rolofylline for Patients Hospitalized with
Acute Decompensated Heart Failure and Volume Overload to
Assess Treatment Effect on Congestion and Renal Function
(PROTECT) trial.16 The PROTECT trial enrolled patients hospital-
ized for AHFS and characterized by the following: (i) normal or
reduced ejection fraction (EF); (iii) persistent dyspnoea at rest or
with minimal activity; (iii) a creatinine clearance of 20–80 mL
min21; (iv) a B-type natriuretic peptide (BNP) level ≥500 pg
mL21 or an N-terminal pro-BNP level ≥2000 pg mL21; and (v)
requiring intravenous (i.v.) loop-diuretic therapy. Participants
were randomly assigned to receive 30 mg of i.v. rolofylline once
daily or matching placebo for up to 3 days. Compared with
placebo, rolofylline did not improve a composite primary
endpoint assessing for death or HF rehospitalization, signs and
symptoms of HF requiring therapeutic intervention, or worsening
renal function.
In the retrospective analysis of the PROTECT trial,15 Metra and
colleagues examined the association between early dyspnoea relief,
defined as moderate or marked improvement at both 24 and 48 h
post-study drug administration, and changes in body weight and
mortality at day 14 and 30. This study makes the following clinically
important contributions to our understanding of the clinical course
of patients hospitalized for AHFS:
(i) Somewhat similarly to previous studies,4,9 –11 50% of
patients did not experience moderate or marked dyspnoea
relief, suggesting that there is room for new therapies to
improve signs and symptoms of HF in this patient population.
(ii) This analysis confirms a key observation from the EVEREST
trial,9 namely the correlation between weight loss during hos-
pitalization and dyspnoea relief.
(iii) Early dyspnoea relief emerges as an important clinical marker
for post-discharge survival.
(iv) Dyspnoea relief was not associated with changes in renal
function during hospitalization, suggesting that these changes
in renal function should not be part of a composite endpoint
in AHFS trials.
However, the most important outcome of this analysis is the
finding that early dyspnoea relief was associated with decreased
post-discharge mortality even after adjusting for known predictors
of prognosis including age, New York Heart Association (NYHA)
functional class, serum creatinine, serum sodium, serum BNP, and
blood pressure. This is an intriguing observation which generates
the hypothesis that dyspnoea may be a suitable surrogate for
safety and/or an endpoint for mortality in AHFS trials. Assuming
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the finding to be valid, dyspnoea would be the ideal primary end-
point for AHFS clinical trials, serving as an indicator of both symp-
tomatic improvement during hospitalization and morbidity and
mortality in the early post-discharge ‘vulnerable’ period. In terms
of clinical trial design, utilizing dyspnoea as a substitute marker
for mortality would require recruiting fewer patients to conduct
a meaningful and appropriately powered study, greatly reducing
the financial burden of new drug development.
However, there are several shortcomings of the data that ques-
tion the internal and external validity of this conclusion. Retrospec-
tive multivariate analysis, by definition, is intrinsically limited by the
inability of the model to correct for unmeasured or unknown con-
founders. Although the authors adjusted for a number of potential
confounders, their multivariate model did not adjust for left ventri-
cular ejection fraction (LVEF), baseline b-blocker, or angiotensin-
converting enzyme (ACE) inhibitor/angiotensin receptor blocker
(ARB) utilization at admission, or inotrope usage or diuretic
dose during hospitalization. In fact, patients reporting early dys-
pnoea relief were more likely to be on a b-blocker or an ACE
inhibitor/ARB at the time of admission and less likely to receive
oral or i.v. inotropes during hospitalization. These observations
suggest that patients experiencing early dyspnoea relief have less
severe HF at baseline and may partially or completely explain
the association between early dyspnoea relief and improved
survival.
The larger scientific question is whether or not there are any
reliable surrogate endpoints for mortality in AHFS trials. Pivotal
clinical trials in AHFS with mortality as an endpoint for safety
and/or efficacy are onerous, logistically complicated, and expensive
to conduct, making it desirable to find a suitable candidate surro-
gate marker for safety and/or mortality. Unfortunately, the avail-
able data suggest that improvements in major clinical predictors
of prognosis including body weight, serum sodium, renal function
parameters, levels of neurohormones, central haemodynamics,
etc. do not translate clinically into a direct mortality benefit
(Table 1).17
Essentially, indicators of prognosis may not necessarily be causa-
tive mediators. In addition, a mediator of outcome for one thera-
peutic intervention may not be a mediator for another novel agent
since known or unknown side effects may obscure any putative
beneficial effects. Thus, we believe that early dyspnoea relief,
even if it is predictive of prognosis in this patient population,
may not be an appropriate surrogate for mortality when studying
novel therapies. For example, in REVIVE II,18 levosimendan treat-
ment facilitated dyspnoea relief, which did not correlate with
improved post-discharge outcomes, because levosimendan treat-
ment was also associated with a propensity for atrial and ventricu-
lar arrhythmias and increased mortality.
Although intriguing, at the present time dyspnoea is not a sub-
stitute for clinical outcomes such as HF rehospitalization and mor-
tality as an endpoint for safety and/or efficacy in AHFS clinical trials.
However, dyspnoea is the most prevalent presenting symptom in
patients hospitalized for HF and thus an important measure of
symptomatic improvement, and continues to be an approval end-
point for the Food and Drug Administration (FDA) and the Euro-
pean Medicines Agency (EMA).15 Thus, dyspnoea will continue to
serve as an efficacy endpoint for short-term symptomatic relief.
However, the importance of dyspnoea as a primary endpoint
should be critically evaluated for the following reasons:
† Standard therapy: the available data suggest that standard
therapy alone appears to relieve dyspnoea and other signs
and symptoms of HF.4,9–11 In fact, patients not experiencing
immediate symptomatic improvement often respond to
additional strategies such as repeated boluses of i.v. loop diure-
tics. As a result, it may be very difficult to ‘beat’ standard therapy
safely. However, the post-hoc analysis by Metra et al. suggests
that dyspnoea may not always be sufficiently treated in at
least a subset of patients hospitalized for AHFS.
† When to measure: global registry4 and clinical trial9–11 data
have shown that the majority of patients are no longer severely
dyspnoeic after 6 h of standard therapy alone unless provoked
(orthopnoea).19 However, it should be noted that many trials
employing baseline dyspnoea as an inclusion criterion and dys-
pnoea reduction as an endpoint have enrolled patients later
(up to 48 h after admission),11 potentially by design leading to
the selection of the patients most refractory to standard
therapy and more likely to present with lower blood pressure
and baseline renal dysfunction, clinical characteristics which
may influence the effects of the agent being tested.
† How to measure: despite the fact that dyspnoea has played a
prominent role as an endpoint in AHFS clinical trials and the
regulatory approval process, most studies have not used a stan-
dardized method (posture, supplemental oxygen status, etc.) to
assess dyspnoea and ensure the reproducibility of data collec-
tion. However, a standard method to measure dyspnoea was
proposed relatively recently.20
† Correlation with a pathophysiological mechanism: patients with
a very high pulmonary capillary wedge pressure (PCWP) may
experience minimal dyspnoea, while patients with a relatively
lower PCWP may be severely dyspnoeic.21 This observation is
complicated by the fact that HF rarely occurs in isolation and
is frequently accompanied by medical co-morbidities (e.g.
chronic obstructive pulmonary disease), which may contribute
to the overall dyspnoeic state through additional pathophysiolo-
gical mechanisms. As a result, the severity of dyspnoea may be
loosely associated with other signs and symptoms of HF, such as
jugular venous distension (JVD) and oedema.
† International variation: it is essential to recognize that dyspnoea
is a self-reported symptom and this subjective sensation may be
perceived very differently by different patient populations. This
hypothesis is further substantiated by the URGENT-dyspnoea
registry,4 which revealed that baseline dyspnoea and manage-
ment show regional differences, implying that results from clini-
cal trials conducted in one region may not be generalized to
another.22
In conclusion, the high prevalence of dyspnoea in patients present-
ing with AHFS underscores its importance as a primary efficacy
endpoint for short-term symptomatic improvement in AHFS clini-
cal trials and the regulatory approval process. If dyspnoea con-
tinues to be an important endpoint for short-term efficacy it
should be measured early, using uniform methods (i.e. provoked
and off oxygen), and correlated with other relevant clinical signs
and symptoms of congestion and biomarkers such as troponin
Editorial 1443
and possibly BNP. It is noteworthy that the majority of clinical trials
conducted in AHFS to date have been negative in terms of efficacy
and/or safety. Clinical trials have been classified as Stage A (short-
term therapy started during initial stabilization in the emergency
department), B (short-term medications aimed at signs and symp-
toms remaining despite initial therapy), and C (long-term therapies
initiated during hospitalization and continued post-discharge).1
Although it is clear that for Stage C clinical trials, mortality and/
or morbidity (HF rehospitalization, etc.) should be the primary effi-
cacy endpoint, it is unlikely that short-term therapeutic interven-
tions tested in Stage A and B clinical trials will reduce
post-discharge mortality unless the short-term therapy prevents
myocardial and/or renal injury, which may occur in a subset of
AHFS patients.23 Given the limitation of utilizing dyspnoea alone
as a primary endpoint, an appropriate efficacy endpoint for a
Stage A and B clinical trial may be a clinical composite.24
Any endpoint that focuses on a single symptom, such as dys-
pnoea alone, at a single point in time ignores other symptoms
and/or biomarkers of congestion and/or myocardial injury that
may be highly relevant to the patient and neglects the possibility
that any benefits may be minor or transient. Hence, a clinical com-
posite (including dyspnoea) may address many of the disadvantages
and biases inherent in an endpoint that focuses on a single
symptom at a single point in time. In the ‘clinical composite
approach’, the patient must report moderate or marked improve-
ment early in the course of therapy, and such improvement must
be sustained throughout the entire duration of the drug’s presence
in the body.
In addition, in the conventional approach, a patient who deterio-
rates and improves solely because of intensification of background
therapy can be considered to be clinically improved. In contrast,
the clinical composite minimizes the noise created by the intensi-
fication of background therapy by excluding from the category of
improvement those patients whose improvement could be
ascribed solely to the use of background therapy (because they
showed symptomatic deterioration during treatment with the
study medication). Finally, in the conventional approach, a patient
who deteriorates and drops out of the study could be excluded
from analyses that focus on the clinical status of patients who com-
plete the study. In contrast, the clinical composite minimizes the
bias inherent in a ‘completers’ analysis by including all patients in
the primary analysis (according to the intention-to-treat principle),
particularly those who dropped out of a study because of worsen-
ing of their clinical course. Thus, composite endpoints that take
into account not only signs and symptoms but also improvement,
or at least preservation, of organ function (e.g. heart and kidney)
may serve as a potential basis for regulatory approval as long as
symptom relief does not occur at the expense of longer term
safety with the degree of ‘acceptable’ risk related to the degree
and type of benefit.
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